final program.qxd - Parallels Plesk Panel

OP 7.3.2
We must Switch Early Patients with Detectable Viremia
CONS
Rita Murri, Roma - Italy
Achieving and maintaining viral suppression less than 50 copies/mL is the goal of current
antiretroviral regimens. Current treatment guidelines suggest that HAART should be
changed after 2 consecutive HIV viral load measurements greater than 400 copies/mL if
tolerable and effective treatment is available. However, the threshold at which therapy
should be switched to optimize patients' future prognosis is unknown.
Even though the rationale for an early change of therapy in presence of a virological
failure is related to the attempt to reduce the chance of developing drug resistance to the
failing regimen, a switch in therapy poses new challenges for tolerability, adherence to a
new regimen, and fit of therapy into the patient's daily routine.
Indeed, despite published recommendations, it seems common in clinical practice that
partial loss of viral suppression is tolerated without an immediate change in regimen,
especially in patients who have limited therapy options.
Several studies will be showed suggesting that even at detectable but moderate levels of
HIV RNA the clinical progression of HIV infection is not significantly different from that of
people with undectable viremia, particularly when HIV RNA was stable and below 10.000
copies/ml. Risks of delaying a switch of therapy will be also discussed and are mainly
related to the appearance of mutations conferring resistance to antiretroviral drugs.
ABSTRACTS
OP 7.4.1
Entry inhibitors have to be spared for advanced stages. PROS
No abstract available
“ Focusing FIRST on PEOPLE “ 61 w w w . i s h e i d . c o m